耐药肺结核病防治研究进展  

Research Progress of Drug Resistant Pulmonary Tuberculosis

作　　者：乔进[1] 张小柏[2] QIAO Jin;ZHANG Xiao-bai(Department of Pharmacy,the Third People′s Hospital of Nantong,Nantong 226006,China;Department of Respiratory Medicine,the Third People′s Hospital of Nantong,Nantong 226006,China)

机构地区：[1]南通市第三人民医院药学部,江苏南通226006 [2]南通市第三人民医院呼吸科,江苏南通226006

出　　处：《海峡药学》2021年第8期75-78,共4页Strait Pharmaceutical Journal

基　　金：江苏省南通卫健委青年医学人才科研基金项目(WR2017011);江苏省南通市临床医学中心项目(HS2016002)。

摘　　要：结核病是一种严重危害民众健康的慢性传染病,尤其是耐多药肺结核的传染周期长,治疗难度大,治疗费用高,治愈率低,死亡率高。耐多药结核病预后较药物敏感性肺结核差,且多影响年轻人,虽然耐多药和广泛耐药肺结核在资源贫乏地区占极小部分,但这些结核菌消耗了结核病规划的不相称比例资源。因此,及早诊断、预防和治疗耐多药结核病非常重要。Tuberculosis is a kind of chronic infectious disease which is a serious harm to the health of people.Especially that the multi drug resistant pulmonary tuberculosis had a long infectious period,had a big difficulty of treatment,and the cure rate was low,the mortality was high.Drug-resistant tuberculosis has poorer outcomes than those drug-susceptible tuberculosis,and frequently affects young adults.Although multidrug-resistant and extensively drug-resistant tuberculosis represent a very small fraction of the total tuberculosis burden in resource-poor setting,these strain consume a disproportionate percentage of resources in tuberculosis programmes.For this reason,it is very important to diagnose,prevent and cure drug-resistant tuberculosis as soon as possible.

关 键 词：肺结核 耐药性 综合预防 治疗 流行病学 

分 类 号：R969.4[医药卫生—药理学]